Dublin-based pharmaceutical company Amarin says there have been positive results from a trial of its AMR101 anti-cholesterol treatment.
The purpose of the trial was to show that AMR101 was effective in reducing triglyceride levels in patients with high triglycerides. Triglycerides are a type of fat, and high levels have been linked with an increased risk of heart disease.
The phase three trial of Amarin's treatment found that it reduced tryglyceride levels significantly in patients.
Amarin CEO Joseph Zakrzewski said the company was delighted with the results. The company says that, in the US alone, 40 million people have high triglyceride levels. The figure is estimated to be 100 million in the world's seven largest pharmaceutical markets.
Amarin board member Dr Manus Rogan said the product was now 'firmly on track to become a multi-billion dollar, blockbuster'. Dr Rogan is managing director of Fountain Healthcare Partners, which led a €70m fund-raising for Amarin 18 months ago.